CytomX Secures $37M Upfront, Up to $4B in Milestones from Expanded Regeneron Cancer Therapy Deal
Summary
CytomX Therapeutics announced an expansion of its strategic research collaboration with Regeneron Pharmaceuticals, securing a $37 million target selection payment for two additional programs. The agreement includes options for Regeneron to select up to six more targets, bringing the total potential milestone payments to approximately $4 billion. This non-dilutive cash infusion and significant potential future payments are crucial for CytomX, which recently reported an 80% Q1 revenue drop and net loss, and completed a $234.4 million dilutive public offering to extend its cash runway. The expanded partnership validates CytomX's PROBODY platform and strengthens its financial position and pipeline development.
At the time of this announcement, CTMX was trading at $3.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $687.9M. The 52-week trading range was $1.72 to $8.21. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.